Syngenta Secures EU Approval For Next Generation Fungicide

          Syngenta Secures EU Approval For Next Generation Fungicide

-- Isopyrazam sets new standard in disease control

-- Consistent crop yield enhancement

-- Product registrations across multiple crops planned

PR Newswire

BASEL, Switzerland, Nov. 13, 2012

BASEL, Switzerland, Nov. 13, 2012 /PRNewswire/ -- Syngenta today announced
that it has received European Union (EU) approval for isopyrazam, the first
active ingredient from its strong pipeline of next generation fungicides.
Approval represents a major step forward in the control of a wide spectrum of
damaging fungal diseases, including best-in-class performance against Yellow

Isopyrazam's advanced "double-binding" technology ensures strong adhesion to
fungus and to leaf wax, providing long-lasting and durable disease protection.

Under the EU's provisional approval system, British and Irish cereal farmers
have for the past two growing seasons experienced the benefits of isopyrazam,
which is marketed as SEGURIS^™ in wheat and BONTIMA^™ in barley. These growers
have consistently achieved better disease control, which has helped deliver
higher crop yields: SEGURIS treatments increase yield by up to two tonnes per
hectare versus current chemistries.

John Atkin, Chief Operating Officer, said: "Breakthrough chemical innovation
is an enduring part of our integrated strategy. Isopyrazam sets the highest
standards for disease control and yield response and this approval means
growers throughout the EU can now benefit from this important addition to our

Syngenta intends to register a range of products containing isopyrazam in
major EU markets for use on cereals and others crops such as oilseed rape,
vegetables and pome fruits.

Syngenta is one of the world's leading companies with more than 26,000
employees in over 90countries dedicated to our purpose: Bringing plant
potential to life. Through world-class science, global reach and commitment to
our customers we help to increase crop productivity, protect the environment
and improve health and quality of life. For more information about us please
go to

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by
terminology such as 'expect', 'would', 'will', 'potential', 'plans',
'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such
statements may be subject to risks and uncertainties that could cause the
actual results to differ materially from these statements. We refer you to
Syngenta's publicly available filings with the U.S. Securities and Exchange
Commission for information about these and other risks and uncertainties.
Syngenta assumes no obligation to update forward-looking statements to reflect
actual results, changed assumptions or other factors. This document does not
constitute, or form part of, any offer or invitation to sell or issue, or any
solicitation of any offer, to purchase or subscribe for any ordinary shares in
Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on
in connection with, any contract therefor.

Syngenta International AG

Media Office
CH-4002 Basel
Tel: +41 61 323 2323
Fax: +41 61 323 2424

Media contacts:

Paul Barrett
Switzerland +41 61 323 2323

Daniel Braxton
Switzerland +41 61 323 2323

Analyst/Investor contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Lars Oestergaard
Switzerland +41 61 323 6793
USA +1 202 737 6520

SOURCE Syngenta

Press spacebar to pause and continue. Press esc to stop.